Cybin (CYBN) Earnings growth forecast for next year

Cybin Inc. - graphic logo of issuer CYBN

Cybin Inc. develops innovative depression treatments leveraging unique patents for modified psilocybin. The consensus growth estimate for net income visualizes market expectations, where 24.00 reflects the latest metric value. The company has earned its status as an ethical pioneer in psychiatry through a rigorous scientific approach while adhering to fundamental environmental standards in its laboratories.

Cybin Inc (CYBN): Expected net earnings per share growth next year from 07/04/2022 to 01/05/2026

Metric breakdowns and analytics for Cybin (CYBN)

- share price and consensus valuation forecast:
Stock Price Cybin Inc|CYBN - Consensus Target
- market capitalization details:
Market Capitalization Cybin|CYBN - Value Adjusted for Debt and Cash
- book capitalization indicators:
Net Assets per Single Share Cybin|CYBN - Total Stockholders' Equity|Market Capitalization to Book Value Ratio cybin.com|CYBN - Cumulative Company Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Cybin Inc.|CYBN - Long-Term Liabilities to Capital|Short-Term Debt to Capital Cybin Inc|CYBN - Company Debts|Debts to Book Capitalization Cybin|CYBN - Long-Term Debt Volume|Company Short-Term Debt Cybin|Quick Liquidity Indicator cybin.com
- net income and valuation ratios data:
CYBN - Final Profit|Projected Future Earnings Cybin Inc.|CYBN - Business Payback Period|Future Price to Earnings Cybin Inc|CYBN - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Cybin|CYBN - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Cybin|CYBN - Net earnings per share for the last four quarters|Quarterly EPS earnings growth cybin.com|CYBN - Net earnings per share growth this year|Expected earnings per share growth for next year Cybin Inc.
Summary company analysis:Cybin Inc., CYBN
Brand item of Cybin

For Cybin Inc. (CYBN), at the stage of clinical trials and patent protection, profit forecasts serve as a leading indicator of future capitalization. This metric aggregates analyst consensus estimates on EPS dynamics, measuring the expected earnings growth rate for the coming year. This chart of the company's expected EPS growth for the next year visualizes institutional confidence in the commercialization of psychedelic therapy. The positive trend confirms market faith in the success of the issuer's R&D strategy.

Competitor analysis

ALKS (Alkermes Inc.) - Earnings growth forecast for next year|Expected earnings per share growth for next year Avadel Corp (AVDL)|Earnings growth forecast for next year ATAI|GHRS (ghres.com) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year MindMed MNMD|COMPASS Pathways PLC (CMPS) - Expected net earnings per share growth next year|LB Pharma - Earnings growth forecast for next year|Bright Minds Corp (DRUG) - Expected earnings per share growth for next year|VNDA (Vanda Pharmaceuticals) - Expected earnings per share growth for next year|Expected net earnings per share growth next year altoneuroscience.com (ANRO)|NRXP (NRx Pharmaceuticals, Inc.) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year CING|Earnings growth forecast for next year SILO|Consensus forecast of earnings per share growth for next year chinapharmaholdings.com|Net earnings per share growth forecast for next year Clearmind Medicine CMND|PBM: Projected earnings per share growth rate for next year|SPRC: Expected earnings per share growth for next year|Expected earnings per share trend next year SEEL (Seelos Therapeutics Inc.)|VRPX: Earnings growth forecast for next year|KRTX - Consensus forecast of earnings per share growth for next year